Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

ClinicalTrials.gov ID: NCT00378131

Public ClinicalTrials.gov record NCT00378131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia

Study identification

NCT ID
NCT00378131
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Enrollment
51 participants

Conditions and interventions

Interventions

  • RC-1291 Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Mar 31, 2007
Completion
Mar 31, 2007
Last update posted
Sep 1, 2013

2006 – 2007

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
16
Facility City State ZIP Site status
Palo Verde Hematology Oncology, Ltd. Glendale Arizona 85304
San Diego Pacific Oncology & Hematology Associates Encinitas California 92024
Sant P. Chawla, MD Santa Monica California 90403
Melbourne Internal Medicine Associates Melbourne Florida 32901
Southwest Oncology Associates Lafayette Louisiana 70503
Center for Cancer and Blood Disorders Bethesda Maryland 20817
Chesapeake Oncology Hematology Associates, PA Glen Burnie Maryland 21061
Beth Israel Cancer Center New York New York 10003
Charleston Cancer Center Charleston South Carolina 29406
South Carolina Oncology Associates, PA Columbia South Carolina 29210
South Carolina Cancer Specialists Hilton Head Island South Carolina 29926
University of Texas Medical Branch Galveston Texas 77555
Michael E. DeBakey VA Medical Center Houston Texas 77030
Cancer Outreach Associates Abingdon Virginia 24211
Virginia Cancer Institute Richmond Virginia 23230
Multicare Health System Tacoma Washington 98405
Northwest Medical Specialties Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00378131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 1, 2013 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00378131 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →